The White House plans to broaden the range of products available through TrumpRx to include generic medications, and billionaire Mark Cuban is scheduled to participate in a rollout at the White House on Monday afternoon, according to reporting that cited people familiar with the matter.
A White House official told reporters that President Donald Trump will announce the expansion of TrumpRx's offerings. The administration has been publicly promoting arrangements with pharmaceutical manufacturers intended to bring down costs for government programs while also making certain drugs available for direct purchase by consumers.
Mark Cuban operates the Mark Cuban Cost Plus Drug Company, a mail-order operation that sells prescription medications directly to consumers with transparent pricing. The participation of Cuban at the White House event highlights the administration's emphasis on direct-to-consumer distribution channels in its effort to address drug affordability.
GoodRx is cited as a principal integration and pricing partner for TrumpRx. Market reaction to the announcement included a 2.9% rise in GoodRx shares during Monday trading, reflecting investor attention to the company's role in the initiative.
Officials have been working with pharmaceutical companies to structure deals that reduce prices for government-run programs while enabling direct sales to consumers, and the planned expansion of TrumpRx is presented by the administration as part of that agenda. The timing of the announcement comes as the administration emphasizes healthcare affordability ahead of the fall midterm elections.
The available reporting identifies the White House announcement, Cuban's attendance, the inclusion of generics on TrumpRx, and GoodRx's role without offering additional operational details or a full list of manufacturers participating in the program. Where information is limited in the reporting, the article reflects those limitations rather than adding details that were not specified.